Immix Biopharma, Inc.
IMMX Nasdaq· Pharmaceutical Preparations
Last close · Oct 23, 2026
$8.15
KIRA · Stoqly’s AI analyst, in plain words
- Immix Biopharma, Inc. lost $29.4M in fiscal 2025.
- Free cash flow was −$24.7M in fiscal 2025, — of revenue.
Market cap
$520M
P/E
—
Revenue
—
Net income
−$29.4M
Free cash flow
−$24.7M
Operating margin
—
Immix Biopharma, Inc. in 30 seconds · fiscal 2025
Does it make a profit?
−$29.4M
No. It lost money last year.
How is the share priced?
—
No P/E: it made no profit over the last four quarters.
What Immix Biopharma, Inc. does
No business description yet.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K · Mar 25, 2026
- Legal name
- Immix Biopharma, Inc.
- CIK
- 0001873835
Immix Biopharma, Inc. · IMMX
Results and finances
The last 5 fiscal years. Amounts in USD.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Sales and profit | |||||
| Net income | −$24.4M | −$8.2M | −$15.4M | −$21.6M | −$29.4M |
| Diluted EPS | −$6.64 | −$0.59 | −$0.89 | −$0.76 | −$0.89 |
| Cash | |||||
| Cash from operations | −$1.6M | −$7.4M | −$11.4M | −$14.6M | −$23.9M |
| Capital expenditure | $0.0M | — | $0.1M | $1.2M | $0.7M |
| Free cash flow | −$1.6M | — | −$11.4M | −$15.8M | −$24.7M |
| Share buybacks | — | $0.1M | — | — | — |
| Share count change | 8.8% | 278.1% | 24.9% | 63.1% | 16.5% |
| Debt and strength | |||||
| Cash and short-term investments | $17.6M | $13.4M | $17.5M | $17.7M | $100M |
| Shareholders' equity | $18.0M | $13.2M | $16.4M | $13.3M | $93.8M |
| Current ratio | 90.0x | 11.7x | 5.3x | 2.3x | 10.0x |
| Interest coverage | −7.5x | −16,437.8x | — | — | — |
| Returns and quality | |||||
| Return on equity | −367.8% | −52.8% | −104.4% | −145.8% | −54.9% |
| Return on tangible equity | −135.5% | −62.5% | −94.0% | −163.1% | −31.3% |
| Altman Z'' | 94.2 | 1.9 | −4.3 | −12.6 | 9.5 |
Insiders bought, 12 months
$0.0M
2 insiders
Insiders sold, 12 months
$0.0M
0 insiders
Of sales under plans
—
$0.0M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Immix Biopharma, Inc. · IMMX
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
KIRA
At $8.15 a share, the company is worth $520M.
Source: SEC EDGAR XBRL filings (CIK 0001873835). Data updated October 24, 2026. For information only — not investment advice. Check the original filings before relying on any figure.